Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment

Abstract

BackgroundThe emergence of proprotein convertase subtilisin/kexin type 9 inhibitors offered dyslipidemia patients an alternative to statins for lipid‐lowering treatment. Understanding patient and physician preferences for lipid‐lowering drugs may promote shared decision‐making and improve treatment outcomes.MethodsThis study utilized an online discrete choice experiment (DCE) to assess the relative importance (RI) of six attributes related to lipid‐lowering drugs, including frequency of administration, mode of administration, reduction of low‐density lipoprotein cholesterol (LDL‐C) level, risk of myopathy, risk of liver damage, and out‐of‐pocket monthly cost. Respondents were recruited from dyslipidemia patients and cardiovascular physicians in China. A mixed logit model and latent class analysis were employed to estimate the preference coefficient, marginal willingness to pay (mWTP), and RI of attributes. Ethical approval has been obtained for this study.ResultsA total of 708 patients and 507 physicians participated in the survey. Patients prioritized the ‘risk of liver damage’ (RI = 23.6%) with ‘mode of administration’ (RI = 19.2%) and ‘frequency of administration’ (RI = 18.8%) following closely. Contrarily, physicians prioritized the ‘reduction of LDL‐C level’ (RI = 33.5%), followed by ‘risk of liver damage’ (RI = 26.0%) and ‘risk of myopathy’ (RI = 16.1%). Patients placed a higher value on ‘frequency of administration’ (p < .001) and ‘mode of administration’ (p < .001) compared to physicians, while physicians valued ‘reduction of LDL‐C level’ (p < .001) and ‘risk of myopathy’ (p = .012) more than patients. Physicians exhibited higher mWTP than patients for all attributes except frequency and mode of administration. The LCA revealed three distinct patient classes: focus on oral administration, focus on hepatic safety and frequency and focus on hepatic safety and cost. Likewise, three physician classes were identified: frequency‐insensitive, efficacy‐focused and safety‐focused.ConclusionsThe preferences for lipid‐lowering drug therapy differed between patients and physicians in China. Physicians should take into account patients' preferences and provide personalized treatment when they formulate lipid‐lowering treatment plans.Patient or Public ContributionPatients participated in the questionnaire design process. They engaged in a focus group discussion to determine attributes and levels and also participated in a pilot survey to assess the comprehensibility of the questionnaires. Additionally, patients were involved in the DCE survey to express their preferences. The findings of patient preference for lipid‐lowering drug therapy will promote shared decision‐making and optimize the treatment regimen.

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis

“…Despite the reduction in price, our study demonstrated that spending on PCSK9 inhibitors increased one year after the policy was implemented, with a notable increase in utilization. Additionally, previous research has indicated that Chinese patients prioritize factors such as efficacy, safety, and mode of administration over OOP cost when selecting lipid-lowering drugs [ 30 ]. This change in priorities can be attributed to the NDPN policy, which has lowered the OOP cost of PCSK9 inhibitors.…”